Over 50 investigator-initiated trials. Refresh 1 in the books refresh 2 starting up. Multiple big-name partners, Biocon Fresenius, Etc. At least one Clinic where it is now standard of care for rhabdo. Let's also not forget the hospital that has purchased more than 1 million dollars worth of the device in a calendar year. By now that hospital is probably not alone in that category. $1000000 is 1000 treatments. Do you think that maybe they got to about 800 treatments and said damn this thing isn't working, but we have money to burn, let's keep buying it?
In Recent quarterly reports and presentations the company had been using the term de-risked. That means they have validation that the product works, they have validation there is a market for the device and they have the ability to turn this into a profitable company.
News 
Market Data 
Discover 
AI
